Is Wegovy a lifetime medication, or is there an end point?

The moment you realise this might not have a clear finish line

You have done the research. You know Wegovy works. But somewhere in the small print a question forms: am I starting something I can never stop? It is a fair thing to sit with before committing to weekly injections. The honest answer is that for some people treatment is genuinely time-limited (a bridge to a lower weight that lifestyle can then sustain) and for others, the biology of obesity means ongoing support gives the best long-term health outcome. Neither group is failing. Obesity is a chronic condition driven by physiology, and Wegovy addresses part of that physiology while you take it.

What the evidence shows clearly is that weight tends to creep back after stopping. In the STEP 1 trial, published in the New England Journal of Medicine, participants who had lost around 15% of their body weight on semaglutide 2.4mg regained much of that within a year of stopping, without any change in diet or activity. That is not because the medicine had been making bad decisions for them; it is because appetite-regulating hormones returned to their pre-treatment state. Knowing this up front lets you plan rather than be surprised.

There is also a misconception worth letting go of gently: that needing to stay on a weight-management medicine long-term is somehow a sign the treatment has not really worked. Someone who manages blood pressure with a daily tablet for decades is not considered a treatment failure. The same logic applies here.

What NICE says, and where private prescribing differs

On the NHS, NICE's appraisal of semaglutide (TA875) recommends it for a maximum of two years, within a specialist weight management service with multidisciplinary support. That two-year limit reflects the conditions under which the NHS commissioned the medicine, and the requirement to stop treatment if less than 5% weight loss is achieved after six months on the maintenance dose. It is a resource and service-design decision as much as a purely clinical one.

Private prescribing sits in different territory. A private prescriber still follows the licensed indication (adults with a qualifying BMI, a weight-related condition where relevant, and no contraindications) but is not bound by the NHS two-year ceiling. Treatment continues for as long as the clinical picture supports it and the patient wants it. That means longer use is possible, but it also means the question of duration gets revisited at every clinical review rather than assumed. You can read more about how Wegovy is used as a weight-management medicine and what the prescribing process looks like from the start.

For anyone already on treatment and wondering whether to continue, the right conversation is with a prescriber who can look at your actual data, how much weight you have lost, how well you have tolerated it, and what your health goals are beyond the number on the scale. That is not a conversation this page can have for you, but it is one our team fields regularly.

What happens to your weight when Wegovy stops

This is where the lifetime-medication question gets its sharpest edge. The data are consistent: weight regain after stopping semaglutide is common and can be substantial. The body's set point, appetite signals and metabolic rate do not permanently reset during treatment. When the medicine clears, those signals reassert themselves. That is not unique to semaglutide, it is a pattern seen across effective weight-management medicines and, to a lesser degree, after significant dietary-only weight loss.

For people whose primary health risk was the weight itself, this matters enormously. For others, perhaps those who used treatment to reach a lower weight at which they could become more active, build better habits, or reduce a specific health risk, the calculus looks different. Some find the lifestyle changes made during treatment persist well enough to limit regain; others find the opposite. There is no reliable way to predict which group you will fall into before you try. The decision about when to stop Wegovy is one worth thinking through with a prescriber well before you reach that point, rather than arriving at it suddenly.

If you are weighing up Wegovy against other options, it helps to understand what Wegovy's medication name refers to and why it matters when comparing treatments, as well as what type of medicine Wegovy is and how it compares to alternatives, including tirzepatide, which works through a dual-receptor mechanism. Our weight-loss treatments page outlines what nume currently offers and what a free consultation involves, with pricing included, no hidden fees, and a prescriber review before anything is dispensed.

Planning a conversation with a prescriber

The most useful thing you can do with the lifetime-medication question is bring it to a prescriber explicitly, before or during treatment. A good prescriber will not give you a vague answer. They will look at why you started, what progress you have made, and what risks are attached to stopping versus continuing. They will also consider tolerability, if side effects have made treatment difficult, that changes the calculation.

At nume, a GPhC-registered prescriber reads your consultation personally before every repeat order. No prescription renews on autopilot. If your circumstances change, or if you want to revisit whether to continue, that review is the place to do it. You can also reach our clinical team through our contact page if something comes up between orders. For a broader look at how semaglutide fits into weight management, the semaglutide overview covers the mechanism, the evidence and what to expect from treatment in plain terms.